What is QTTB's current stock price?

QTTB (Q32 Bio Inc.) is currently trading at $5.80 with a market cap of $74.1M.

What sector is Q32 Bio Inc. in?

Q32 Bio Inc. (QTTB) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is QTTB a good stock to buy?

Analysts have a Buy consensus on QTTB with a price target of $13.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

QTTB Q32 Bio Inc.

Healthcare

$5.80+5.45%ClosedMarket Cap: $74.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

2.43

PEG

0.01

P/B

1.77

P/S

1.38

EV/EBITDA

1.55

DCF Value

$3.19

FCF Yield

-37.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

99.5%

Operating Margin

39.8%

Net Margin

61.9%

ROE

230.7%

ROA

52.2%

ROIC

36.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-7.6M	$—
Q4 null	$53.7M	$57.7M	$—
FY null	$53.7M	$29.8M	$—
Q3 null	$0.00	$-7.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$13.50

Target (Median)

$13.50

Target Range

$13.00 - $14.00

0 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-05

Trading Activity

Insider Trades

View All

Violette Shelia M.officer: Chief Scientific Officer

SellFri Mar 20

Morrison Jodie Popedirector, officer: CEO

SellFri Mar 20

Kalowski Leeofficer: CFO and President

SellFri Mar 20

Violette Shelia M.officer: Chief Scientific Officer

SellFri Feb 27

Morrison Jodie Popedirector, officer: CEO

SellFri Feb 27

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-1.27

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Peers